About NovioSense BV
NovioSense BV: Revolutionizing Diabetes Management with Innovative Technology
NovioSense BV is a Dutch-based company that specializes in developing innovative technology for diabetes management. The company is located at Novio Tech Campus Nijmegen, which is a European and global hotspot for high tech and health companies. NovioSense BV has been at the forefront of developing cutting-edge technology that can help people with diabetes manage their condition more effectively.
The company was founded in 2012 by Dr. Christopher Wilson, who has over 20 years of experience in the medical device industry. Dr. Wilson's vision was to create a non-invasive glucose monitoring system that could provide accurate readings without requiring patients to prick their fingers multiple times a day.
Since its inception, NovioSense BV has been dedicated to developing innovative solutions for diabetes management. The company's flagship product is the Tear Glucose Monitor (TGM), which uses tear fluid instead of blood to measure glucose levels in the body.
The TGM consists of a small sensor that is placed on the lower eyelid and collects tear fluid throughout the day. The sensor then transmits this data wirelessly to a mobile app or other device, allowing patients and healthcare providers to monitor glucose levels in real-time.
One of the key advantages of using tear fluid instead of blood for glucose monitoring is that it eliminates the need for painful finger pricks. This can be especially beneficial for children or individuals who have difficulty managing their condition due to fear or discomfort associated with traditional testing methods.
In addition, because tear fluid provides continuous glucose monitoring (CGM) data throughout the day, it can help patients make more informed decisions about diet, exercise, and medication dosages based on real-time information about their glucose levels.
Another advantage of using tear fluid as opposed to blood is that it provides more accurate readings than traditional CGM systems. This is because tear fluid contains many biomarkers that are directly related to glucose metabolism in the body.
NovioSense BV's Tear Glucose Monitor has undergone extensive clinical trials and received regulatory approval from both European and US authorities. The company plans to launch its product commercially soon after receiving FDA clearance later this year.
In addition to its work on diabetes management technology, NovioSense BV also collaborates with other companies and research institutions on various projects related to health innovation. For example, they are currently working with Radboud University Medical Center on developing new diagnostic tools for infectious diseases such as COVID-19.
Overall, NovioSense BV represents an exciting development in diabetes management technology by providing an innovative solution that eliminates pain while providing accurate readings through continuous monitoring via tears rather than blood samples taken from finger pricks multiple times per day like traditional methods require!
noviotechcampus.com
